ANGIOGRAPHIC LESION SIZE ASSOCIATED WITH LOC387715 A69S GENOTYPE IN SUBFOVEAL POLYPOIDAL CHOROIDAL VASCULOPATHY
暂无分享,去创建一个
[1] Y. Tano,et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. , 2010, Ophthalmology.
[2] H. Iijima,et al. Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy. , 2008, American journal of ophthalmology.
[3] F. Tsai,et al. HTRA1 POLYMORPHISM IN DRY AND WET AGE-RELATED MACULAR DEGENERATION , 2008, Retina.
[4] M. Brantley,et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.
[5] Akira Negi,et al. LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. , 2007, American journal of ophthalmology.
[6] Michael D. Ober,et al. SELECTIVE PHOTODYNAMIC THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH POLYPOIDAL CHOROIDAL NEOVASCULARIZATION , 2007, Retina.
[7] M. Brantley,et al. Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. , 2007, American journal of ophthalmology.
[8] A. Tsujikawa,et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. , 2007, American journal of ophthalmology.
[9] I. Maruko,et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. , 2007, American journal of ophthalmology.
[10] H. Imaizumi,et al. Photodynamic Therapy for Age-Related Macular Degeneration in Japanese Patients: Results After One Year , 2007, Japanese Journal of Ophthalmology.
[11] J. Haines,et al. Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration. , 2007, American journal of ophthalmology.
[12] B. Rosner,et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. , 2007, JAMA.
[13] W. März,et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. , 2007, Ophthalmology.
[14] Y. Tano,et al. Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[15] M. Mandai,et al. HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY , 2007, Retina.
[16] H. Kawakami,et al. A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population , 2007, Neuroscience Letters.
[17] Chi Pui Pang,et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. , 2007, Science.
[18] N. Camp,et al. A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.
[19] S. Fisher,et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .
[20] T. Iida. [Diagnostic criteria for polypoidal choroidal vasculopathy and their clinical significance]. , 2005, Nippon Ganka Gakkai zasshi.
[21] J. Cunha-Vaz,et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.
[22] S. Natarajan,et al. Role of photodynamic therapy in polypoidal choroidal vasculopathy. , 2005, Indian journal of ophthalmology.
[23] T. Lai,et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.
[24] N. Bressler. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. , 2003, American journal of ophthalmology.
[25] M. Matsumura,et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. , 2003, Archives of ophthalmology.
[26] Michael Stur,et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.
[27] J. Slakter,et al. TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY , 2002, Retina.
[28] L. Yannuzzi,et al. Idiopathic polypoidal choroidal vasculopathy of the macula. , 1998, Ophthalmology.
[29] L. Yannuzzi,et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. , 1997, Archives of ophthalmology.
[30] Lars G Fritsche,et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. , 2005, Human molecular genetics.
[31] J. Slakter,et al. INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY , 1995, Retina.
[32] L A Yannuzzi,et al. IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV) , 1990, Retina.